keyword
MENU ▼
Read by QxMD icon Read
search

mRcc

keyword
https://www.readbyqxmd.com/read/28230776/effects-and-side-effects-of-using-sorafenib-and-sunitinib-in-the-treatment-of-metastatic-renal-cell-carcinoma
#1
REVIEW
Caroline Randrup Hansen, Daniela Grimm, Johann Bauer, Markus Wehland, Nils E Magnusson
In recent years, targeted therapies have proven beneficial in terms of progression-free survival (PFS) and overall survival (OS) in the treatment of metastatic renal cell carcinoma (mRCC). The tyrosine kinase inhibitors (TKIs) sorafenib and sunitinib are included in international clinical guidelines as first-line and second-line therapy in mRCC. Hypertension is an adverse effect of these drugs and the degree of hypertension associates with the anti-tumour effect. Studies have compared newer targeted drugs to sorafenib and sunitinib in terms of PFS, OS, quality of life and safety profiles...
February 21, 2017: International Journal of Molecular Sciences
https://www.readbyqxmd.com/read/28224821/lenvatinib-for-use-in-combination-with-everolimus-for-the-treatment-of-patients-with-advanced-renal-cell-carcinoma-following-one-prior-anti-angiogenic-therapy
#2
Aine O'Reilly, James Larkin
In patients with mRCC options for second line therapies, following progression on anti-angiogenic agents, that demonstrate a survival advantage in clinical trials have been limited. Recently a number of agents have demonstrated efficacy in this setting. Here in we profile one such therapy, the combination of lenvatinib and everolimus, and discuss the expanded options for therapy available in this setting. Areas covered: In this review, we discuss current algorithms for treatment of mRCC in both the first-line and second-line setting...
March 2017: Expert Review of Clinical Pharmacology
https://www.readbyqxmd.com/read/28220024/molecular-subtypes-improve-prognostic-value-of-international-metastatic-renal-cell-carcinoma-database-consortium-prognostic-model
#3
Guillermo de Velasco, Aedín C Culhane, André P Fay, A Ari Hakimi, Martin H Voss, Nizar M Tannir, Pheroze Tamboli, Leonard J Appleman, Joaquim Bellmunt, W Kimryn Rathmell, Laurence Albiges, James J Hsieh, Daniel Y C Heng, Sabina Signoretti, Toni K Choueiri
INTRODUCTION: Gene-expression signatures for prognosis have been reported in localized renal cell carcinoma (RCC). The aim of this study was to test the predictive power of two different signatures, ClearCode34, a 34-gene signature model [Eur Urol 2014;66:77-84], and an 8-gene signature model [Eur Urol 2015;67:17-20], in the setting of systemic therapy for metastatic disease. MATERIALS AND METHODS: Metastatic RCC (mRCC) patients from five institutions who were part of TCGA were identified and clinical data were retrieved...
February 20, 2017: Oncologist
https://www.readbyqxmd.com/read/28216279/outcomes-and-drug-costs-of-sunitinib-regimens-for-metastatic-renal-cell-carcinoma-a-provincial-population-based-study
#4
Aleksi Suo, Urooj Iqbal, June Lim, Chel Lee, Kathy Gesy, Nayyer Iqbal, Tahir Abbas
BACKGROUND: Conventional sunitinib dosing in metastatic renal cell carcinoma (mRCC) administers 50 mg daily on a 4 weeks on/2 weeks off (4/2) schedule. Not all patients tolerate this regimen and many undergo modifications to schedule, dose, or both. MATERIAL AND METHODS: All patients with mRCC treated with sunitinib by the Saskatchewan Cancer Agency between January 1, 2006, and January 1, 2013, were included. Regimens were categorized as standard intermittent dosing (SID), modified intermittent schedule (MIS), modified intermittent dosing (MID), combination of modified schedule and dosing (MSD), or continuous dosing (CD)...
February 1, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28216278/outcomes-of-patients-with-metastatic-renal-cell-carcinoma-and-bone-metastases-in-the-targeted-therapy-era
#5
Sarathi Kalra, Jonathan Verma, Bradley J Atkinson, Surena F Matin, Christopher G Wood, Jose A Karam, Sue-Hwa Lin, Robert L Satcher, Pheroze Tamboli, Kanishka Sircar, Priya Rao, Paul G Corn, Nizar M Tannir, Eric Jonasch
BACKGROUND: Bone metastases (BMs) occur commonly in patients with metastatic renal cell carcinoma (mRCC). Tyrosine kinase inhibitors (TKIs) have improved the outcomes for patients with mRCC. However, data on the outcomes of mRCC patients with BMs treated with TKIs are limited. We describe the outcomes of patients with BMs treated with TKI therapy and compare them with the outcomes from a pre-TKI group. PATIENTS AND METHODS: Using an institutional tumor registry, a retrospective review of patients with mRCC from 2002 to 2003 and 2006 to 2007 was performed...
January 18, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28216276/prediction-of-everolimus-toxicity-and-prognostic-value-of-skeletal-muscle-index-in-patients-with-metastatic-renal-cell-carcinoma
#6
Edouard Auclin, Camille Bourillon, Eleonora De Maio, Marie Agnes By, Sofiane Seddik, Laure Fournier, Marie Auvray, Antoine Dautruche, Yann-Alexandre Vano, Constance Thibault, Florence Joly, Laurent Brunereau, Carlos Gomez-Roca, Christine Chevreau, Reza Elaidi, Stéphane Oudard
BACKGROUND: The objective of the study was to assess the prognostic role of skeletal muscle index (SMI) in metastatic renal cell carcinoma (mRCC) patients treated with everolimus, and its effect of on everolimus-induced toxicity. PATIENTS AND METHODS: Consecutive mRCC patients treated with everolimus between February 2007 and November 2014 underwent computed tomography scans at a single center performed by the same radiologist. SMI was assessed before everolimus treatment using the L3 cross-sectional area...
February 1, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28213730/impact-of-baseline-visceral-fat-accumulation-on-prognosis-in-patients-with-metastatic-renal-cell-carcinoma-treated-with-systemic-therapy
#7
Ryuichi Mizuno, Akira Miyajima, Taizo Hibi, Aya Masuda, Toshiaki Shinojima, Eiji Kikuchi, Masahiro Jinzaki, Mototsugu Oya
The aim of this study was to evaluate the clinical significance of visceral fat accumulation as a prognostic factor in patients with metastatic renal cell carcinoma (mRCC) treated with systemic therapies. A total of 114 patients were retrospectively reviewed. All patients received systemic therapy for mRCC at Keio University hospital in Japan. The intra-abdominal visceral fat area was determined by computed tomography at the umbilical level. The visceral fat accumulation was defined as ≥100 cm(2). The mean visceral fat area was 107...
April 2017: Medical Oncology
https://www.readbyqxmd.com/read/28199818/cabozantinib-versus-sunitinib-as-initial-targeted-therapy-for-patients-with-metastatic-renal-cell-carcinoma-of-poor-or-intermediate-risk-the-alliance-a031203-cabosun-trial
#8
Toni K Choueiri, Susan Halabi, Ben L Sanford, Olwen Hahn, M Dror Michaelson, Meghara K Walsh, Darren R Feldman, Thomas Olencki, Joel Picus, Eric J Small, Shaker Dakhil, Daniel J George, Michael J Morris
Purpose Cabozantinib is an oral potent inhibitor of vascular endothelial growth factor receptor 2, MET, and AXL and is a standard second-line therapy for metastatic renal cell carcinoma (mRCC). This randomized phase II multicenter trial evaluated cabozantinib compared with sunitinib as first-line therapy in patients with mRCC. Patients and Methods Eligible patients had untreated clear cell mRCC and Eastern Cooperative Oncology Group performance status of 0 to 2 and were intermediate or poor risk per International Metastatic Renal Cell Carcinoma Database Consortium criteria...
February 20, 2017: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28196874/prospective-evaluation-of-sunitinib-induced-cardiotoxicity-in-patients-with-metastatic-renal-cell-carcinoma
#9
Vivek Narayan, Stephen M Keefe, Naomi Haas, Le Wang, Igor Puzanov, Mary E Putt, Anna Catino, James Fang, Neeraj Agarwal, David Hyman, Amanda M Smith, Brian S Finkelman, Hari K Narayan, Steven Ewer, Chantal ElAmm, Daniel J Lenihan, Bonnie Ky
PURPOSE: To prospectively evaluate cardiotoxicity risk with sunitinib in metastatic renal cell carcinoma (mRCC) routine clinical practice using comprehensive echocardiography and biomarker phenotyping. PATIENTS AND METHODS: In a multi-center prospective study of 90 mRCC patients, echocardiography and biomarkers of cardiovascular injury and stress were quantified at baseline, 3.5, 15, and 33 weeks following sunitinib initiation. These "on-drug" visits corresponded to cycles 1, 3, and 6, respectively...
February 14, 2017: Clinical Cancer Research: An Official Journal of the American Association for Cancer Research
https://www.readbyqxmd.com/read/28188447/a-prospective-observational-study-on-the-evaluation-of-everolimus-related-adverse-events-in-metastatic-renal-cell-carcinoma-after-first-line-anti-vascular-endothelial-growth-factor-therapy-the-afinite-study-in-france
#10
Florence Joly, Jean-Christophe Eymard, Laurence Albiges, Thierry Nguyen, Aline Guillot, Frederic Rolland, Dominique Spaeth, Brigitte Laguerre, Thierry Lebret, Nadia Kelkouli, Khemaies Slimane, Alain Ravaud
PURPOSE: The objective of the study was to describe the occurrence of stomatitis and noninfectious lung disease in patients with metastatic renal cell carcinoma (mRCC) treated with second-line everolimus in a real-world setting. METHODS: This multicenter, prospective, observational study was conducted in France by physicians with experience of treatment of patients with mRCC. Patients aged ≥18 years who received everolimus after first-line antivascular endothelial growth factor (VEGF) therapy were included in the study...
February 10, 2017: Supportive Care in Cancer: Official Journal of the Multinational Association of Supportive Care in Cancer
https://www.readbyqxmd.com/read/28188047/pretreatment-serum-prealbumin-as-an-independent-prognostic-indicator-in-patients-with-metastatic-renal-cell-carcinoma-using-tyrosine-kinase-inhibitors-as-first-line-target-therapy
#11
Wen Cai, Wen Kong, Baijun Dong, Jin Zhang, Yonghui Chen, Wei Xue, Yiran Huang, Lixin Zhou, Jiwei Huang
BACKGROUND: Although serum prealbumin is a sensitive marker to assess malnutrition, its prognostic impact in patients with metastatic renal cell carcinoma (mRCC) remains elusive. METHODS: Patients' data were retrospectively retrieved from the medical records of Renji Hospital affiliated to Shanghai Jiao Tong University School of Medicine from March 2006 to July 2015 to access overall survival (OS) and progression-free survival (PFS). The survival outcomes of patients with low pretreatment prealbumin (< 200 mg/L) and high pretreatment prealbumin (≥ 200 mg/L) were compared using a log-rank test and Cox proportional hazard regression model...
January 18, 2017: Clinical Genitourinary Cancer
https://www.readbyqxmd.com/read/28183256/current-and-emerging-treatments-for-metastatic-renal-cell-carcinoma
#12
Carla Cavaliere, Carmine D Aniello, Chiara Della Pepa, Salvatore Pisconti, Massimiliano Berretta, Gaetano Facchini
In the last decades the treatment of mRCC, metastatic Renal Cell Carcinoma, has become more and more complex due to the approval of a great number of effective systemic treatments that have significantly improved the prognosis of patients suffering from such disease. An increasing knowledge of the genetic aberrations and the molecular pathways alterations that underlie RCC, has promoted the development of several novel agents, known as target therapies (TTs). Even though TTs are not curative and all patients eventually progressed, an adequate sequencing of these drugs can provide a significant benefit in terms of PFS, Progression Free Survival, and hopefully OS, Overall Survival...
February 8, 2017: Current Cancer Drug Targets
https://www.readbyqxmd.com/read/28169111/expression-pattern-of-immune-checkpoint-associated-molecules-in-radical-nephrectomy-specimens-as-a-prognosticator-in-patients-with-metastatic-renal-cell-carcinoma-treated-with-tyrosine-kinase-inhibitors
#13
Takuto Hara, Hideaki Miyake, Masato Fujisawa
OBJECTIVE: To analyze the expression pattern of immune checkpoint-associated molecules in tumor tissues to determine the prognostic significance of these molecules in patients with metastatic renal cell carcinoma (mRCC) treated with tyrosine kinase inhibitors (TKIs). METHODS: Radical nephrectomy specimens were obtained from 62 patients treated with TKIs as first-line systemic therapy for mRCC. The proportions of programmed death-1 (PD-1)-positive tumor infiltrating lymphocytes (TILs) as well as those of tumor cells positive for PD-ligand 1 (PD-L1) and PD-L2 were analyzed by immunohistochemical staining...
February 3, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28153420/the-independent-oncological-role-for-cytoreductive-nephrectomy-in-metastatic-renal-cell-carcinoma-prognostic-features-in-the-era-of-targeted-therapies
#14
Tom Claeys, Nicolaas Lumen, Candy Kumps, Marleen Praet, Gert De Meerleer, Sylvie Rottey, Piet Ost, Pieter Devisschere, Geert Villeirs, Valerie Fonteyne, Karel Decaestecker
OBJECTIVES: To describe the effects of cytoreductive nephrectomy (CN) on the natural course of metastatic renal cell carcinoma (mRCC). CN appears to stabilize metastatic lesions in mRCC in a subgroup of patients and we hypothesize that systemic treatment might be deferred in these patients with stable disease after CN. SUBJECTS AND METHODS: Overall, 45 patients with mRCC who underwent CN and subsequent oncologic follow-up were included in this retrospective, single-center analysis...
January 30, 2017: Urologic Oncology
https://www.readbyqxmd.com/read/28152737/financial-risk-sharing-agreements-using-options-to-make-marginal-benefits-cost-effective
#15
(no author information available yet)
: 41 Background: New cancer treatments have become increasingly costly. Although new drugs may be sufficiently cost-efficiency for a primary indication (i1) to receive funding, subsequent indications (ia) may not prove cost-effective. A financial risk-sharing agreement to increase access is proposed. A potential 2012 real-world implementation in Canada for pazopanib use in metastatic renal cell carcinoma (mRCC) as i1, and soft-tissue sarcoma (STS) as ia is presented. METHODS: The market value of an indication can be approximated by its net-present-value (NPV) of expected cash flows...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28152689/comparative-effectiveness-research-in-renal-cell-carcinoma-lenvatinib-with-everolimus-as-a-potential-new-treatment-option
#16
Corey Pelletier, Unnati Majethia, Anna Forsythe
: 27 Background: Renal cell carcinoma (RCC) is the most common type of kidney cancer and represents about 90% of all kidney cancers. As comprehensive comparison of the efficacy associated with mRCC treatments is not available, the goal of this research was to provide a comparative effectiveness analysis including overall survival (OS) and progression free survival (PFS) for first and second line treatments. METHODS: Systematic literature review yielded the following randomized active-controlled studies: lenvatinib + everolimus (LEN+EVE) versus everolimus (EVE), axinitib (AXI) versus sorafenib (SOR), cabozantinib (CAB) versus EVE, nivolumab (NIV) versus EVE, and pazopanib (PAZ) versus sunitinib (SUN)...
March 2016: Journal of Clinical Oncology: Official Journal of the American Society of Clinical Oncology
https://www.readbyqxmd.com/read/28144152/overall-survival-in-renal-cell-carcinoma-after-introduction-of-targeted-therapies-a-norwegian-population-based-study
#17
Christian Beisland, Tom B Johannesen, Olbjorn Klepp, Ulrika Axcrona, Knut Martin Torgersen, Jan Kowalski, Oddvar Solli, Rickard Sandin, Jan Oldenburg
BACKGROUND: This population-wide retrospective, non-interventional registry study assessed changes in overall survival (OS) and factors influencing OS in Norwegian patients with renal cell carcinoma (RCC). METHODS: Two population-wide health registries were used to identify all RCC patients with (mRCC) or without metastases diagnosed before (2002-2005) and after (2006-2008 and 2009-2011) introduction of targeted therapies. Median OS was estimated using Kaplan-Meier method...
2017: OncoTargets and Therapy
https://www.readbyqxmd.com/read/28144093/managing-metastatic-renal-cell-carcinoma-challenges-pitfalls-and-outcomes-in-the-real-world
#18
Karnam Ashok Kumar, Gundeti Sadashivudu, K V Krishnamani, Vijay Gandhi Linga, Lakshmi Srinivas Maddali, Raghunadha Rao Digumarti
INTRODUCTION: Renal cell carcinoma (RCC) is the most common cancer of the kidney accounting for 85% of renal tumors. Metastatic RCC (mRCC) had a poor prognosis and with the introduction of tyrosine-kinase inhibitors, such as sunitinib, pazopanib the outcomes improved. There is only one study reported from India on the use of sunitinib in mRCC. We present our analysis of mRCC and use of sunitinib at our institute over 5 years. MATERIALS AND METHODS: All patients with mRCC receiving sunitinib were analyzed with respect to patient characteristics, response, toxicity, and outcomes...
October 2016: Indian Journal of Medical and Paediatric Oncology
https://www.readbyqxmd.com/read/28143997/targeted-therapy-for-metastatic-renal-cell-carcinoma
#19
REVIEW
Andika Afriansyah, Agus Rizal Ah Hamid, Chaidir A Mochtar, Rainy Umbas
In the past 10 years, recent development of targeted therapy in metastatic renal cell carcinoma (mRCC) has provided a new hope and significantly enhanced the prognosis of the disease. Three class of targeted therapy were developed, including multi-targeted tyrosine kinase inhibitors (TKI), the mammalian target of rapamycin (mTOR) complex-1 kinase inhibitors, and the humanized antivascular endothelial growth factor (VEGF) monoclonal antibody. Hence, the objective of this article was to critically examine the current evidence of targeted therapy treatment for patients with mRCC...
October 2016: Acta Medica Indonesiana
https://www.readbyqxmd.com/read/28130612/assessment-of-response-to-anti-angiogenic-targeted-therapy-in-pulmonary-metastatic-renal-cell-carcinoma-r2-value-as-a-predictive-biomarker
#20
Guangyu Wu, Guiqin Liu, Wen Kong, Jianxun Qu, Shiteng Suo, Xiaosheng Liu, Jianrong Xu, Jin Zhang
PURPOSE: To evaluate the utility of MR R2*-mapping and the optimal time-point for assessing the response of pulmonary metastatic renal cell carcinoma (mRCC) to anti-angiogenic targeted therapy (aATT). MATERIALS AND METHODS: The exploration-sample group and the validation-sample group consisted of 22 and 16 patients. The parameters of MR R2*-mapping, including the R2* value at each time-point (R2*base, R2*1cyc and R2*2cyc) and change between different time-points (R2*(1cyc-base)/base, R2*(2cyc-base)/base and R2*(2cyc-1cyc)/1cyc), were evaluated with a receiver-operating-characteristic analysis, and a cut-off value derived from the clinical outcome was applied to the Kaplan-Meier method to assess the value of R2* mapping and Response-Evaluation-Criteria in Solid Tumours (RECIST) during treatment evaluation...
January 27, 2017: European Radiology
keyword
keyword
77808
1
2
Fetch more papers »
Fetching more papers... Fetching...
Read by QxMD. Sign in or create an account to discover new knowledge that matter to you.
Remove bar
Read by QxMD icon Read
×

Search Tips

Use Boolean operators: AND/OR

diabetic AND foot
diabetes OR diabetic

Exclude a word using the 'minus' sign

Virchow -triad

Use Parentheses

water AND (cup OR glass)

Add an asterisk (*) at end of a word to include word stems

Neuro* will search for Neurology, Neuroscientist, Neurological, and so on

Use quotes to search for an exact phrase

"primary prevention of cancer"
(heart or cardiac or cardio*) AND arrest -"American Heart Association"